Welcome to J.B.CHEMICALS AND PHARMACEUTICALS LTD.

Mission & Vision

JBCPL aims to manufacture affordable products that improve lives across the globe. Providing medicines of the highest quality to our customers, is very much part our mission. We endeavour to please every JBCPL client and stakeholder through focus, hard work and honesty. Our vision is to become one of the leading global generic manufacturers of quality pharmaceutical products by excelling in the fields of research, regulatory and manufacturing.

Innovation

We believe that innovation is essential to developing a world class pharmaceutical company especially in a globalised world. That’s why we aim to develop new products that cater to every population.As diseases change and grow, innovation is the only way to truly succeed. Keeping apace with an ever dynamic health industry is absolutely fundamental to our lives as well to those we are trying to save.

PatentsNDDS patents granted in the United States of America for controlled release formulations of Ranitidine and topical dental formulations of Metronidazole and Chlorhexidine for periodontal treatment 

Patents have also been granted in

• South Africa for controlled release formulations of Ranitidine and Nifedipine extended release tablets.
• USA for novel pharmaceuticals formulation of Metronidazole for dental applications
• USA for Patent for Controlled Release Formulation of Ranitidine
• Russia and Kazakhstan for “Doktor Mom” Herbal Cough Remedy

The US and South African Patent Offices have granted patents for all the NCEs invented by the company in the therapeutic category of NSAID. A similar application has already been forwarded to the European Union Authorities for filing this patent.

International Patents Granted 24
Domestic Patents Granted 15

QualityOur commitment to quality is firm. This is why we run our entire production process with a battery of quality-control tests conducted using state-of-the art laboratory testing equipment. The strict quality assurance standards maintained at every single manufacturing plant have earned certificates for ‘Good Manufacturing Practices’ under the WHO’s GMP certification scheme. 

The Company holds DMFs for Diclofenac Sodium, Diclofenac Potassium, Diclofenac Acid and Nifedipine. The manufacturing plant for Diclofenac Sodium, Diclofenac Potassium has been approved by the USFDA. 

Additionally, the company’s formulation manufacturing plants at various locations hold approvals from authorities like the USFDA, UK MHRA, TGA Australia, MCC South Africa and authorities from Germany, Latvia, Ukraine and other African countries. 

It comes as no surprise that JBCPL is one of the first Asian companies to obtain a Certificate of Suitability to European Pharmacopoeia Monograph for Metronidazole, Nifedipine and Diclofenac Sodium. 

With these international accreditations, the company thrives on high-quality standards and its products are truly competitive in the international market.

R & D

• ANDAs filed and approved
• R & D has developed an anti-infective Ornidazole P Ointment topical gel. Clinical trials completed successfully.
• Cilnidipine, a new type of Dihydropyridine, for hypertension, successfully developed. R&D has completed optimising the formula and process for an antihypertensive Cilnidipine tablets 10/20 mg.
• Developed cough suppressant lozenges using an ion exchange mechanism to mask the bitter taste of the drug.
• Novel drug delivery systems developed and completed optimising the formula and process for platform technology using an osmotic-controlled drug delivery system.
• Developed a process for Gadopentetic Acid, which is used for formulating an MRI contrast medium.
• Developed Ciprofloxacin XR once daily dosage by using a patented gastro-retentive system.
• Pioneered a revolutionary new process for the manufacture of Metronidazole from its initial stage.
• Two product patents obtained from the US Patent & Trademark office for the topical application of Metronidazole and PVP iodine.
• The second company in India to receive the Drug Controller General of India’s permission to market Ofloxacin once a day 400mg & 800mg formulations.
• J.B.Chemicals & Pharmaceuticals Ltd. is the first Asian Company to obtain the prestigious new EP4 European Certification for its API Nifedipine, Metronidazole and Diclofenac Sodium.
• Two product patents from the US Patent & Trademark office for Dental Formulations
• Developed several novel formulations, the significant ones being Metrogyl Denta and Metrogyl Vaginal Gel.

TechnologyThe company has 17 manufacturing plants in two cities producing a diverse range of active pharmaceutical ingredients, drug intermediates, pharmaceutical formulations, contrast media and herbal remedies. In response to an ever-competitive global environment, JBCPL has established an ultra-modern export-oriented unit with a unique design that guarantees safety, purity, and quality. The protection of the environment is also a major part of our corporate philosophy. We have effective water and air pollution control systems in all our plants in an effort to minimize all wastage. 

Examples of JBCPL’s constant endeavour to stay technologically advanced are: 

• The Rommelag Aseptic Form-Fill-Seal Technology for production of intravenous fluids.
• Ultra-modern facilities for intravenous formulations and ointments, with the layout and design as per the cGMP concept laid down by the top regulatory authorities.
• A sophisticated and automated lozenges manufacturing facility at Daman.

Read more